VolitionRx Q1 2026 revenue $1.0M; $5M milestone potential from feline lymphoma test

VOLITIONRX LTD

2026-Q1 EPS reported -$0.97 revenue$985,076

Revenue of $1.0M in Q1 2026 vs $0.2M in Q1 2025; operating loss decreased 3% YoY.
Net cash used in operations was $5.3M; raised $5.4M from ATM equity and $1.9M from convertible note.
Received $1M in non-dilutive Walloon Region funding; ~$0.9M more expected over 12 months.
Feline lymphoma assay manuscript submitted for peer review; expected to unlock $5M milestone payment.
Discussions ongoing with >12 diagnostic companies for licensing; Nu.Q Lung Cancer reimbursement in France progressing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

VOLITIONRX LTD reported the first quarter 2026 results: revenue $1.0 million.

Period: the first quarter 2026
Revenue: $1.0 million
Result: reported results

Exact text from the filing

pillars; our laser focus is on executing licensing agreements and we will update you as they progress.” 1 Financial Highlights · Revenue for the first quarter was approximately $1.0 million, compared to $0.2 million for the same period in 2025. · Operating loss was down 3% for the quarter versus the comparable quarter in 2025. · Net cash used in operating activities

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

VOLITIONRX LTD filing history →

Source: SEC EDGAR

accession 0001477932-26-003126

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.